Using biologics to treat stricturing Crohn's disease

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to evaluate the efficacy of biologic treatments in patients with stricturing Crohn's disease who do not have surgical indications. It seeks to gather prospective data, as previous findings were largely retrospective, to better understand how biologics can help manage this condition. Patients will be treated with biologics while being monitored for their response to the therapy. The study is being conducted at Jinling Hospital in Nanjing, China.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* patients with stricturing Crohn's diseases
* no surgical indication
* patients with asymptomatic penetrating diseases
* written consent acquired

Exclusion Criteria:

* patients with surgical indication
* patients with symptomatic penetrating diseases
* contraindication of biologics
* anticipating other trial

Where it's running

• Department of General Surgery, Jinling hosptal,Medical School of Nanjing University
  Nanjing, Jiangsu, China Recruiting

Study contacts

• Principal investigator: Weiming wm Zhu, Ph.D. — Jinling Hospital, China
• Study coordinator: Weiming wm Zhu, Ph.D.
• Email: juwiming@nju.edu.cn
• Phone: +86-025-80863736

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Brown fat activity after cold exposure measured by PET/CT in healthy people and those with metabolic conditions

  This study tests how brown adipose tissue responds to cold exposure using PET/CT in adults aged 18-40, including some with diabetes or high cholesterol.

  Recruiting Jinling Hospital, China · Nanjing, Jiangsu · NCT07908719

• Peg IFNα-2b plus targeted immunotherapy for unresectable HBV-related HCC

  This study tests whether adding pegylated interferon alpha-2b to targeted immunotherapy can help patients with unresectable HBV-related liver cancer stay or improve beyond standard nucleoside therapy.

  Recruiting Jinling Hospital, China · Nanjing, Jiangsu · NCT07769827

• Perioperative UDCA to Protect Kidney Function in Partial Nephrectomy

  This study tests whether giving ursodeoxycholic acid around surgery can help protect kidney function in adults having partial nephrectomy for kidney tumors.

  Recruiting Phase 2 Jinling Hospital, China · Nanjing, Jiangsu · NCT07672860

• CD70-Targeted Imaging-Guided Pause of Therapy in Metastatic Clear Cell RCC

  This study tests whether patients with metastatic clear cell RCC who respond to first-line PD-1/PD-L1 inhibitors plus VEGFR-TKI can safely pause treatment guided by CD70-targeted Immuno-PET/CT imaging.

  Recruiting at 5 sites Phase 2 Jinling Hospital, China · Nanjing, Jiangsu and 4 other locations · NCT07615348

• Gut microbiota modulation to retry immunotherapy in advanced kidney cancer

  This trial tests whether changing gut bacteria can help people with advanced renal cell carcinoma respond again to immunotherapy after resistance.

  Recruiting Phase 2 Jinling Hospital, China · Nanjing, Jiangsu and 1 other locations · NCT07611825

• Impact of Surgical Treatment on Survival in Localized Small Cell Esophageal Cancer

  This study looks at whether surgery improves survival for people with localized small cell esophageal cancer compared with non-surgical treatment.

  Recruiting Jinling Hospital, China · Nanjing, Jiangsu · NCT07596654

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.